EZH2 and small cell lung carcinoma: In CheckMate 032, for both Nivolumab and combination cohort, a high expression of LSD1 was significantly associated with worse OS (P = 0.02), and same trend was found for EZH2 (P = 0.27) (48), opening up the understanding of epigenetic modification predicting the efficacy of immunotherapy in SCLC.